Effectiveness of Intravitreal Bevacizumab Monotherapy in the Treatment of Retinopathy of Prematurity: An Experience of a Tertiary Care Hospital in Central Punjab
Prospective study on intravitreal bevacizumab shows effective treatment outcomes for ROP in preterm neonates, emphasizing its advantages over laser therapy.
Key Points
IVB monotherapy achieved complete regression in 23 out of 31 treated neonates with Stage 3 ROP, showing significant effectiveness.
Among 463 screened neonates, 115 had ROP, indicating a frequency of about 24.8% in this population.
This prospective interventional study included preterm neonates treated at a tertiary care facility over 18 months, using structured assessments.
These findings highlight IVB as a safe and effective alternative in resource-limited settings where laser therapy may not be accessible.